Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Mass-Producing Natural Cancer-Killing Cells for Treatment Options for Patients

By BiotechDaily International staff writers
Posted on 27 Mar 2013
Scientists reported that they are in the process of generating natural cancer-killing cells in the laboratory in a quantity that could soon make them feasible for treating patients.

Even though the production of human natural killer (NK) cells in the lab from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) has become routine, it has been on a limited scale. But a new study’s findings demonstrate how to increase the number of resulting cells while in addition decreasing the amount of work and time involved in generating them. “NK cells show promise for cancer therapy,” said Dan Kaufman, MD, PhD, of the Stem Cell Institute, University of Minnesota (UM; Minneapolis; USA). “They are part of the innate immune system and exhibit potent antitumor activity without the need for donor matching and prior treatment. Moreover, the derivation of NK cells from pluripotent stem cells could provide an unlimited source of lymphocytes for ‘off-the-shelf’ therapy.”

Dr. Kaufman was the lead investigator of the study that included colleagues from UM as well as from the Integrated Center of Cellular Therapy and Regenerative Medicine, St. Anne’s University Hospital Brno (Brno, Czech Republic); and the University of Texas (Houston, USA). The study’s findings were published March 20, 2013, in the journal STEM CELLS Translational Medicine.

“Human NK cells have been used to treat patients with refractory malignancies, but a major hindrance to expanded use has been the inefficiency of production,” said Anthony Atala, MD, editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC, USA). “The current study has identified a two-stage culture system to efficiently produce the cells in a manner more suitable to clinical translation than previous methods.”

Related Links:

Stem Cell Institute, University of Minnesota



Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.